Lenalidomide is a medication used primarily to treat certain blood cancers and multiple myeloma. It belongs to a class of drugs known as immunomodulatory agents. The drug works by enhancing the immune system's ability to recognize and destroy cancer cells. It also modifies the activity of certain signaling proteins that promote tumor growth. By inhibiting these pathways Lenalidomide helps reduce the proliferation of malignant cells. Overall it serves as a targeted therapy that improves disease control in patients with approved cancers.

Lenalidomide is a medication that modulates the immune system and is used in certain cancers. It works by changing the levels of signaling proteins that regulate cell growth and survival. The drug promotes activity of immune cells that target malignant cells and limits the formation of new blood vessels that feed tumors. Its pharmacological action involves binding to a cellular protein that triggers the breakdown of key transcription regulators. This degradation alters pathways that control inflammation and cell cycle progression, leading to the intended therapeutic effect. Overall Lenalidomide provides clinical benefit by precisely shaping the cellular environment that supports tumor growth.

Lenalidomide is used in certain cancer treatments and inflammatory conditions. The most frequently reported side effects include low white blood cell counts. Tingling or numbness in the hands and feet can also occur. Some patients experience fatigue or weakness. Nausea and mild diarrhea are also observed in many cases. Less often, skin rashes or itching may develop. Laboratory tests often show changes in kidney function.

Fatigue, diarrhea, and nausea are among the most frequently reported side effects of Lenalidomide. Fever, rash, and mild infections may also occur during treatment. Patients often experience decreased appetite and occasional dizziness. Blood cell counts such as white blood cells and platelets can be impacted temporarily. These effects are typically monitored through regular laboratory tests. Most reactions are mild and do not require discontinuation of therapy.